Irlanda - anglès - HPRA (Health Products Regulatory Authority)

vetoquinol sa - pyrantel embonate ; praziquantel; febantel - tablet - 144, 50, 150 mg/tablet - febantel, combinations

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150, 144, 50 mg/tablet - combinations of tetrahydropyrimidines

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150, 144, 50 mg/tablet - praziquantel, combinations

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

vetoquinol sa - praziquantel; pyrantel embonate ; febantel - tablet - 175, 504, 525 mg/tablet - combinations of tetrahydropyrimidines

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

servier laboratories sa (pty) ltd - tablet - each tablet contains indapamide 0,625 mg perindopril arginine 2,5 mg

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

servier laboratories sa (pty) ltd - tablet - each tablet contains indapamide 2,5 mg perindopril tert-butylamine 8,0 mg

Estats Units - anglès - NLM (National Library of Medicine)

organon llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in

Regne Unit - anglès - myHealthbox

bayer ag -

Regne Unit - anglès - myHealthbox

bayer ag -

Israel - anglès - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin - sitar plus is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use: sitar plus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. sitar plus has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitar plus.